Navigation Links
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
Date:6/1/2008

100%, with 53% of evaluable MTC patients (9 of 17) experiencing partial responses. With a single exception, all of the evaluated MTC patients had reductions in the MTC-associated plasma markers calcitonin and carcinoembryonic antigen. Most of the MTC patients in the trial had previously failed other treatments, including tyrosine kinase inhibitors with anti-RET activity (e.g., vandetanib, sorafenib, motesanib), chemotherapeutics, immunotherapy, radioactive iodine, and radiotherapy.

"Patients with medullary thyroid cancer are a highly underserved population as there is no active approved therapy available at this time. Targeted therapeutics, such as dual inhibitors of RET and VEGFR2, are the first compounds showing activity in this disease. The phase 1 results of XL184, the first such molecule in this class also to inhibit the oncogenic MET receptor, were reported today by Drs. Salgia and Kurzrock, and are remarkable, both in terms of the high frequency of responses and how rapidly they occur," said Steven I. Sherman, MD, Chair and Professor, Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M.D. Anderson Cancer Center, Houston, Texas. "I am looking forward to the phase 3 trial of XL184 in this indication and believe that studies like this will importantly advance the care of patients with medullary thyroid cancer."

The data indicate that XL184 was generally well-tolerated at the MTD of 175 mg QD (capsule). Adverse events related to study drug included diarrhea, nausea, fatigue, mucositis, anorexia, elevation of liver enzymes, hypertension, vomiting, hair hypopigmentation, and palmar-plantar erythema. Dose-limiting toxicities included palmar-plantar erythema, elevation of liver enzymes, lipase elevation, and mucositis.

Pharmacokinetic analyses indicate that the half-life of XL184 was approximately 100 hours (range 59-136 hours), with exposure at the MTD exceeding that required for efficacy in preclinical models. Pharma
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), a ... announced today that they are starting production of the ... is designed for placement inside optical shops and Eye ... there are over 20,000 optical stores in America.  ... first automated kiosk dedicated to cleaning and sanitizing eyeglasses ...
(Date:9/22/2014)... 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) ... 2014 ended July 31, 2014 on Monday, September 29 before ... the results at 11:00 AM ET. Participating in the call ... A. Krakauer , President and CEO; Jorgen B. Hansen ... , Senior Vice President, CFO and Treasurer; and Seth ...
(Date:9/22/2014)... Pa. , Sept. 22, 2014  Inovio ... today it has initiated a phase I clinical ... will evaluate the safety, tolerability, and immunogenicity of ... (HPV-6), which causes most aerodigestive cancers. ... throat, vocal cords, and parts of the esophagus ...
Breaking Medicine Technology:Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
(Date:9/22/2014)... (September 22, 2014) McMaster scientists have found that ... class of antibiotics. , Although dozens of antibiotics ... how a certain part of bacteria are created, and ... , The discovery is important as there is ... the cures for infections ineffective. The World Health Organization ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 This Flash ... on stakeholder management needs for the Prostate Cancer market. ... Experts on stakeholder strategies for any launching Prostate Cancer ... of differentiation within an increasingly crowded market , ... The impact of identifying community-based thought leaders and stakeholders ...
(Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
(Date:9/22/2014)... New York, New York (PRWEB) September 22, 2014 ... risks associated with the use of power morcellators ... Liebhard LLP notes a new report detailing the ... despite warnings from federal regulators that specifically discouraged ... these physicians believe that the potential cancer risks ...
(Date:9/22/2014)... Bronson Gray HealthDay Reporter ... pregnant woman wonders: What can I do to help ensure ... supplements as prescribed may play a role in reducing the ... The researchers found that mothers of children with autism ... and during pregnancy than those whose children seem to be ...
Breaking Medicine News(10 mins):Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
... , , , ... Carefx Corporation , a leading provider of interoperable workflow solutions ... one of its clients, the Louisiana Rural Health Information Exchange (LARHIX), was ... Information Executives , a top healthcare information technology magazine. , ...
... , , LAKE ... ), a leading global specialty pharmaceutical and medication delivery company, today ... sales for the quarter were $957 million, and adjusted* diluted earnings ... described later in this press release and the attached schedules.) , ...
... , PITTSBURGH, July 29 Mylan Inc. ... its executive management team. The changes, which reflect internal promotions and ... , Heather Bresch has been promoted to president. ... leadership responsibilities related to the day-to-day operations of the company. She ...
... , , , ... WPI ), a leader in generic and specialty branded pharmaceuticals, today ... Excluding special items as detailed in the reconciliation table below, adjusted ... per diluted share, an increase of $15.8 million or 29 percent. ...
... , , SAFETY ... Prevention Specialist, like many, did not start out with a drug-free ... fought his own battle with substance abuse that ended with his ... , After successfully completing treatment at Narconon, John decided ...
... ... are delighted to announce their partnership to better meet the needs of the autism community in ... ... and AutismOne are delighted to announce their partnership to better meet the needs of ...
Cached Medicine News:Health News:Top Healthcare Magazine Awards Carefx Client '2009 IT Project of the Year' 2Health News:Top Healthcare Magazine Awards Carefx Client '2009 IT Project of the Year' 3Health News:Hospira Reports Second-Quarter 2009 Results 2Health News:Hospira Reports Second-Quarter 2009 Results 3Health News:Hospira Reports Second-Quarter 2009 Results 4Health News:Hospira Reports Second-Quarter 2009 Results 5Health News:Hospira Reports Second-Quarter 2009 Results 6Health News:Hospira Reports Second-Quarter 2009 Results 7Health News:Hospira Reports Second-Quarter 2009 Results 8Health News:Hospira Reports Second-Quarter 2009 Results 9Health News:Hospira Reports Second-Quarter 2009 Results 10Health News:Hospira Reports Second-Quarter 2009 Results 11Health News:Hospira Reports Second-Quarter 2009 Results 12Health News:Hospira Reports Second-Quarter 2009 Results 13Health News:Hospira Reports Second-Quarter 2009 Results 14Health News:Hospira Reports Second-Quarter 2009 Results 15Health News:Hospira Reports Second-Quarter 2009 Results 16Health News:Hospira Reports Second-Quarter 2009 Results 17Health News:Hospira Reports Second-Quarter 2009 Results 18Health News:Hospira Reports Second-Quarter 2009 Results 19Health News:Hospira Reports Second-Quarter 2009 Results 20Health News:Hospira Reports Second-Quarter 2009 Results 21Health News:Hospira Reports Second-Quarter 2009 Results 22Health News:Hospira Reports Second-Quarter 2009 Results 23Health News:Hospira Reports Second-Quarter 2009 Results 24Health News:Hospira Reports Second-Quarter 2009 Results 25Health News:Hospira Reports Second-Quarter 2009 Results 26Health News:Hospira Reports Second-Quarter 2009 Results 27Health News:Hospira Reports Second-Quarter 2009 Results 28Health News:Mylan Announces Enhancements to Executive Management Team 2Health News:Mylan Announces Enhancements to Executive Management Team 3Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 5
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: